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Abstract
Cell replacement therapy is a viable option for the treatment of Huntington's disease 
(HD), where the aim is to replace the lost medium spiny projection neurons of the stria‐
tum. The intra‐striatal engraftment of developing striatal precursors harvested from the 
foetal brain has provided proof of concept in both rodent models and human patients that 
these primary foetal tissue grafts can bring about a degree of functional recovery in a HD‐
degenerated brain. With the advent of pluripotent stem cell technologies, novel, potential 
alternative donor cell sources have become available. Ongoing studies are assessing the 
capacity of these cells to differentiate towards striatal precursors for transplantation in 
HD. Here, we review the characteristics of potential donor cells for HD with respect to 
available cell markers, functional properties and maturity of cells upon transplantation. 
We consider the optimal composition of the donor cell population, that is, whether a 
heterogeneous population containing all cell types from the developing striatum (the 
whole ganglionic eminence) is preferable to a more homogeneous population of striatal 
projection neurons, as directed by differentiation protocols applied to pluripotent stem 
cells. Furthermore, we consider what might be required to improve transplant efficacy 
and success, with respect to striatal differentiation of transplanted cells and functional 
improvement.
Keywords: neural transplantation, primary foetal tissue, pluripotent stem cells, striatal 
medium spiny neurons, DARPP‐32
1. Introduction
The application of cell transplantation as a therapeutic for the neurodegenerative disease 
Huntington's disease (HD) offers to replace those striatal cells lost to the disease. Medium‐
sized spiny projection neurons (MSNs) of the striatum are the predominant cell type lost, and 
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it is these cells which we endeavour to replace  in order to initiate reconstruction of the dam‐
aged circuitry and alleviate some of the symptoms associated with the disease. This specific 
and focal loss of MSNs in HD makes it an ideal candidate for cell replacement therapy.
Cells from the developing striatum (named the whole ganglionic eminence (WGE); the stria‐
tal primordia), harvested during the window of striatal neurogenesis and implanted into the 
HD brain, have shown beneficial effects with a degree of functional recovery in preclinical 
rodent studies and in ‘proof‐of‐principle’ clinical trials, see [1–3]. This indicates that intra‐
striatal transplantation of developing MSNs has the potential to alleviate some aspects of 
this disease. All clinical investigative studies of transplantation in HD have, to date, utilised 
human primary foetal tissue as the donor tissue [2, 3], where developing striata are harvested 
from multiple embryos obtained after elective termination of pregnancy. This donor tissue 
source has many limitations associated with it, leading to the ongoing quest to find an alterna‐
tive cell source that can fulfil the requirements for successful transplantation, integration and 
functional improvements.
In this chapter, we will discuss the use of human primary foetal tissue, and what we know 
to date with respect to intra‐striatal transplantation of this donor tissue source in the HD 
paradigm. The unanswered questions related to this donor source will be assessed, includ‐
ing what the optimal parameters might be for transplantation. We will consider the need for 
alternative donor cell sources and will look at the characteristics of potential alternative donor 
cell sources, and in particular, their ability to generate striatal MSNs in vitro and post‐trans‐
plantation and the factors potentially influencing their ability to improve function following 
transplantation.
2. Primary foetal tissue
It is well documented that the gold standard donor cell source for neural transplantation 
in HD is primary foetal tissue [4], where cells are taken from the developing brain from the 
region of origin of the desired mature cells and within an appropriate gestational window. 
Striatal MSNs originate in the WGE, which is situated within the developing telencephalon, 
and can be harvested easily using microdissection techniques [5, 6]. This can be straightfor‐
ward depending on the method of tissue collection (i.e. medical versus surgical termination of 
pregnancy: MTOP and STOP, respectively), CNS tissue being more accurately dissected from 
MTOP‐derived tissue than STOP‐derived tissue due to less fragmentation of MTOP tissue, 
thereby enabling easier identification of different regions [7]. Thus, as a source of donor cells 
for transplantation, there has been a progressive move to the use of MTOP rather than the 
much more limited supply of STOP tissue. This in part reduces, albeit to a small extent, some 
of the logistical burden associated with the use of foetal tissue for cell replacement therapy. 
However, there are unknowns and limitations associated with the use of primary foetal tis‐
sue, which will be discussed in detail later.
Initial studies of cell transplantation in HD have provided accumulative evidence of the con‐
ditions for safety and preliminary evidence for clinical efficacy. There have been seven small 
clinical transplantation studies reported to date, all of which have used primary foetal striatal 
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tissue as the donor cell source [8–14]. Safety and feasibility of bilateral intra‐striatal transplan‐
tation in HD patients have been shown [8–11].
Utilising magnetic resonance imaging (MRI), the trial based in California, USA [8], indicated 
graft survival in all three of their transplanted patients at 1‐year post‐transplantation. A sepa‐
rate trial, based in Florida, USA, reported a decrease in the Unified Huntington's disease 
rating scale (UHDRS) score at 12‐months post‐transplantation, suggesting an improvement 
in motor function [11]. The INSERM trial, conducted in Créteil in France, provided more 
solid efficacy data [15]. Out of five patients with HD who received bilateral striatal implants 
of foetal WGE tissue, three had surviving grafts as evidenced by changes in MRI signal and 
increased metabolic activity in the graft regions on 18F‐FDG positron emission tomography 
(PET). The three patients with surviving grafts were reported to show substantial motor and 
cognitive improvements at 1‐year post‐transplantation, as assessed using the Core Assessment 
Program for Intracerebral Transplantation in Huntington's Disease (CAPIT‐HD) [15]. At 6‐
years post‐transplantation, again using the CAPIT battery, the over‐riding message from 
this trial was the stability of the disease progression; in particular, the choreatic movements 
experienced by the patients remained stable, at an improved level for 4–6 years [16]. Further 
reports employing imaging techniques following striatal transplantation in HD have shown 
metabolically active tissues [14] and increased striatal D2 receptor binding with PET [12]. In 
addition, data from the Florence cohort of eight patients showed a degree of stabilisation or 
improvements in some neurological indices over 18‐ to 34‐months post‐transplantation [14], 
whilst the London cohort revealed some clinical improvement over 5‐years post‐transplanta‐
tion [12].
The longest clinical follow‐up assessment post‐transplantation reported comes from the 
Cardiff‐Cambridge, UK trial [17]. Data are presented for clinical outcome measures up to 
10‐year post‐transplantation. They report a ‘trend towards a slowing of progression’, and 
although there were improvements found on certain measures for individual patients, 
there were no overall statistically significant improvements found in CAPIT scores between 
grafted patients and a non‐grafted reference group. However, data obtained from PET imag‐
ing showed no obvious surviving graft tissue, and the authors postulate that the grafts were 
insufficiently large to produce a clinical benefit. Overall, the aforementioned trials have sug‐
gested that intra‐striatal grafting is feasible and largely safe; disease progression has not been 
reported to accelerate in transplanted patients [10], and for patients showing no indication of 
graft benefits, progression of the disease appears similar to that seen in non‐grafted patients 
[16]. These studies have also shown that human foetal striatal transplants can survive long 
term and can bring about functional benefits to symptomatic HD patients in at least some 
cases. What is less clear currently is what factors are important for producing graft‐related 
benefit in a more reliable fashion. Potential contributing factors that need to be considered for 
successful primary foetal striatal transplants include gestational age of donor tissue, tissue 
dissection, tissue preparation, number of cells transplanted and selection of graft recipient, 
among others, reviewed in [18].
In addition to the clinical data discussed above, there are a number of published reports of 
post‐mortem analyses from these transplant trials [13, 19–23]. The earliest post‐mortem time 
was 6‐month post‐transplantation [13], and in this study, the authors reported graft‐derived 
Transplantation in HD: Are We Transplanting the Right Cells?
http://dx.doi.org/10.5772/66490
121
DARPP‐32 (dopamine‐ and cyclic‐AMP‐regulated phosphoprotein of molecular weight 
32 kDa), NeuN, calretinin, somatostatin and GFAP, as well as graft innervation of host‐derived 
tyrosine hydroxylase fibres. Markers of more immature precursors were also present, includ‐
ing doublecortin, Sox2 and Ki67 [13]. One patient from the Florida cohort died 18‐month 
post‐transplantation due to cardiovascular disease, and post‐mortem analysis showed surviv‐
ing graft tissue, which was positive for striatal markers such as acetylcholinesterase (AChE), 
calbindin and calretinin, as well as innervating tyrosine hydroxylase‐positive processes [21]. 
Moreover, there was no evidence of immune rejection in the graft region or evidence that the 
graft was affected by the underlying disease progression [21]. Analysis of a graft from the 
California cohort also showed no signs of rejection or evidence of HD‐related pathology in 
the graft [20]. However, this latter study, reporting on one patient at 10‐year post‐transplanta‐
tion, revealed the presence of multiple mass lesions and cysts, suggestive of graft overgrowth. 
Additionally, although calretinin, calbindin, parvalbumin and neurofilament markers were 
reported, only rare neuronal projections traversing the graft‐host boundary were noted [20]. 
One post‐mortem study from the Florida trial, 10‐year post‐transplantation, demonstrated 
graft survival with expression of markers of striatal projection neurons and interneurons and 
evidence of synaptic connections between transplanted neurons and host‐derived dopami‐
nergic and glutamatergic neurons, but also suggested some degeneration of grafted neurons 
[22]. A further post‐mortem analysis from the Florida cohort, up to 12‐year post‐transplanta‐
tion, observed that there were both fewer blood vessels and fewer astrocytes in the graft com‐
pared with the surrounding host tissue, which together may result in reduced trophic support 
to the graft and impact on graft survival [23]. However, these grafts also showed some typi‐
cal striatal graft morphology in which there were regions of the grafts that were positive for 
AChE, termed p‐zones, as well as areas with no expression of AChE, termed non‐p‐zones [23].
Overall, it can be said that the data obtained from these limited numbers of transplant trials 
are somewhat mixed, in terms of both clinical outcomes and post‐mortem analyses. It is dif‐
ficult to draw any direct comparisons between data from the various studies because of the 
differences between studies in the protocols for tissue dissection, preparation, transplanta‐
tion, immunisation and patient assessments, thus highlighting the need to undertake better 
controlled studies with common protocols to allow comparison of results between centres, 
reviewed in [3, 18].
3. What do we still need to know about human foetal WGE in order to 
improve graft reliability?
Although both animal research and clinical research into foetal striatal transplantation for HD 
span over two decades, several important issues relating to the optimal conditions for use of 
this tissue as a donor source of cells remain. The success of neural transplantation depends on 
harvesting the foetal tissue from the appropriate part of the developing CNS, at the appropri‐
ate gestational age, and for the preparation to be optimised to maximise cell viability.
The first unknown is how to optimise the dissection of the developing foetal striatum. During 
development, the striatum forms as two ridges in the floor of the embryonic lateral ventricles: 
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the lateral and medial ganglionic eminences (LGE and MGE, respectively). DARPP‐32‐pos‐
itive MSNs derive predominantly from the LGE [24], whilst striatal interneurons are pre‐
dominantly derived from the MGE [25]. Based on this, it has previously been proposed that 
deriving donor cells from the LGE, rather than WGE, would generate a purer population of 
MSNs and that this would produce an improved graft [26–29]. However, studies of rodent‐to‐
rodent grafts show similar behavioural improvement in both LGE‐ and WGE‐derived grafts, 
although the overall striatal graft volumes and mean numbers of striatal‐like neurons were 
greater in the WGE‐derived grafts. Thus, contrary to expectation, it is suggested that the pres‐
ence of interneurons from the MGE may facilitate graft survival and integration, thus favour‐
ing a WGE‐derived cell population for transplantation [29–31]. Studies of human foetal brain 
samples show DARPP‐32‐positive MSNs beginning to appear in the LGE from 7‐weeks post‐
conception with the number increasing over the following 2 weeks [32, 33], but to date there 
have been no systematic studies using human foetal donor tissue in animal models to address 
the issue of ‘optimal dissection’, largely due to the scarcity of tissue.
It is known that the foetal gestational age is important in deriving donor cells that will go on 
to produce a functional graft, but a second unknown is the optimal foetal donor age for this 
purpose. In rodent studies, it has been shown that grafts derived from embryonic day (E) 
14–E16 rat donors generate a higher proportion of striatal‐like tissue compared with grafts 
derived from older embryonic tissue [30]. However, functional recovery was only seen in 
those recipients who received transplants from the younger E14 donors [34]. This has not 
been systematically investigated to date in any one, single study for human foetal samples. 
Thus, it is necessary to draw what we can from the published literature in which a range 
of ages from 6‐ to 14‐week gestation has been used [35–38]. It has been shown that human 
foetal WGE cells harvested at 7‐ to 9‐week post‐conception [37] and also at 14‐week post‐con‐
ception [36] are able to ameliorate the apomorphine‐induced deficits seen in animals having 
received unilateral excitotoxic striatal lesions, which mimic the pattern of cell loss seen in HD. 
In agreement with these earlier studies, we too see an improvement in apomorphine‐induced 
rotations using human foetal WGE at 8‐week post‐conception [38]. Furthermore, improve‐
ment was also seen in the vibrissae‐evoked forepaw placing test, as well as stabilisation over 
time in the adjusting steps test [38]. Together these studies build on the histological assess‐
ments of cell survival and integration. As described above, clinical trials have utilised tissue 
in the range of 6‐ to 12‐week gestation, making this a potentially significant source of varia‐
tion. Thus, despite the logistical difficulties (largely due to the uncertainties of foetal tissue 
availability) of undertaking comparisons of different gestational ages of human foetal WGE 
human to rat grafts, this is clearly a critical factor that needs to be extensively and systemati‐
cally addressed.
A third factor to be considered is the way in which the foetal donor tissue is prepared prior 
to transplantation. Two broad approaches have been used to date: the crude chopping of the 
tissue into smaller pieces [8, 9, 11] and the mechanical dissociation of the tissue with the aid 
of enzymes [10, 12, 14]. As with the previous issues, there is again limited systematic evidence 
supporting either method. One study that examined this issue directly (using rodent tis‐
sue) reported a greater proportion of striatal‐like tissue in conjunction with more DARPP‐32 
immunopositive neurons within grafts derived from dissociated cell suspensions compared 
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to grafts derived from tissue fragments [39]. Conversely, a modest improvement in functional 
recovery on the paw‐reaching test was seen in animals receiving tissue fragment grafts com‐
pared to suspension grafts [39]. With current legislation pertaining to good manufacturing 
practice (GMP), there is a need to replicate this study using non–animal‐derived products and 
so replacing the classical trypsin approach with GMP‐compatible products.
In light of what has been discussed above, it is clear that there are many unknowns when it 
comes to the transplantation of human foetal striatal tissue in HD. It is critical that the ques‐
tions raised above are not dismissed as new cell sources are investigated, and one key step 
in preclinical validation of these alternatives will be to compare them to primary foetal tissue 
transplants. One important consideration relates to the functional readout from such studies, 
especially given the limited data thus far generated from transplants of human foetal tis‐
sue [35–38]; some rodent studies have highlighted the plasticity of striatal grafts, which can 
have implications on functional effects post‐transplantation [40–44]. It has been shown that 
animals post‐transplantation need to ‘re‐learn’ a task that had been well established prior to 
induction of the lesion, using the 9‐hole box operant chamber [40]. Here, it was reported that 
simply reforming the circuitry in the brain was not enough to achieve functional benefit, but 
instead the animals needed a period of time to re‐train in order to make use of the recon‐
structed circuitry. A similar strategy using a different task, the paw‐reaching/staircase test, 
also showed the benefits of additional training post‐transplantation [41].
Another important consideration which might enhance functional recovery in human foetal 
striatal transplant studies is the role for environmental enrichment which has been shown to 
favourably affect the behavioural readout in rodent allograft experiments [45]. Housing ani‐
mals in an enriched environment post‐transplantation resulted in larger projection neurons 
with increased spine density and better graft re‐innervation [45, 46]. In addition, levels of 
BDNF in the intact side of the brain were increased in both transplanted and non‐transplanted 
animals that were exposed to environmental enrichment compared with those in standard 
housing [43, 45, 46]. Furthermore, the impact of the enriched environment on the plasticity 
of striatal grafts has also been shown electrophysiologically, by measurement of long‐term 
potentiation (LTP), which indicates persistence of synaptic strength. LTP was more readily 
induced in the grafts where hosts had received enrichment compared with those where hosts 
were in standard conditions [44, 47, 48].
In the studies of human foetal tissue transplants in animal models described above, the 
behavioural effects reported have been limited to drug‐induced rotations, vibrissae‐evoked 
touch test and adjusting steps test, and so far no effect has been reported on the paw‐reach‐
ing test [35–38]. However, to date, neither the approach of additional training to allow trans‐
planted animals to re‐learn a task post‐transplantation, and learn to use the graft, nor the 
environmental enrichment strategy has been applied to human foetal striatal transplant stud‐
ies. One limitation of behavioural analysis in xenotransplantation studies is the restricted 
time window post‐transplantation due to the need for daily immunosuppression. Despite 
the presence of DARPP‐32‐positive cells in the brains of these animals upon post‐mortem 
analysis, transplanted human foetal striatal cells might require a longer time in vivo in order 
to achieve a functional readout as seen in the equivalent rodent studies. One way of overcom‐
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ing this would be to use the ‘neonatal desensitisation’ approach, which negates the need for 
daily immunosuppression [49]. However, this too has its own limitations not least the lack of 
understanding behind its mechanism of action.
4. Are foetal donor cells a long‐term prospect?
There are a number of advantages associated with the use of human foetal striatal donor 
cells. The prime advantage is, as discussed above, the generation of MSNs that have been 
exposed to patterning signals during natural development and are thus likely to be ‘authen‐
tic’ MSNs with the greatest ability to bring about functional improvement in HD models and 
HD patients. However, there are additional advantages associated with the lineage‐restricted 
nature of these cells, in particular, that there is a reduced risk of non‐neural cells arising from 
the graft, and thus a much reduced risk of graft overgrowth and/or teratoma formation. These 
factors are why, currently, human foetal WGE cells are the ‘gold standard’ with which newer 
donor sources need to be compared. However, the continued use of human WGE cells in 
both animal and human studies extends beyond the simple comparison of efficacy. Given the 
uncertainties of the current clinical studies outlined above, there is a need for further proof‐
of‐concept studies and to gain further insight into factors important for graft optimisation, 
including not only considerations of the donor cells, but also factors such as optimum host 
age and stage of disease. Moreover, understanding in more detail how foetal cells survive and 
integrate will be crucial in learning how to generate effective cells from other starting sources 
such as human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.
Nevertheless, although it is important to continue to study human foetal WGE for the reasons 
above, it is unlikely that they will be sufficient to achieve widespread clinical application due 
to several ethical and logistical issues. First, the scarcity of this tissue supply is limiting. This 
is complicated by the requirement to use multiple donors per patient; some studies have used 
up to eight foetal donors per patient for a bilateral transplant, albeit that many studies have 
used 1–3, see [3]. It is also further limited by the need to harvest cells at the point of peak MSN 
neurogenesis, believed to be in the range of 8‐ to 12‐week post‐conception, thus further reduc‐
ing the number of suitable, potential donor tissue retrievals. Moreover, the shift in working 
practices at gynaecological units means that the STOP tissue source is becoming even more 
rare and the MTOP tissue, due to the very nature of the procedure, can in some cases be 
completed in the comfort of the person's own home, thus limiting the supply being procured 
through hospital facilities. A second issue is that following dissection, the tissue cannot be 
stored for long periods of time (maximum of 8 days) [50, 51]. Therefore, coordinating the tis‐
sue collection and transplantation can be logistically challenging. The organisational network 
that needs to be in place in order for clinical transplants to take place is exceptionally complex, 
in particular, the coordination of timing of foetal tissue collection (which it is not possible to 
manoeuvre), with the neurosurgical procedure. Another point to be mentioned (related to 
the inability of this tissue to be hibernated) is that the cells cannot be subject to full screening, 
tissue typing, etc, as they can't be stored for long enough to complete such assessments, prior 
to transplantation. These considerable limitations associated with the use of primary foetal 
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tissue have led to the search for possible alternative donor cell sources to permit more wide‐
spread and better controlled transplant processes for the future.
5. Alternative donor cell sources
Desirable characteristics of donor cells to replace foetal WGE cells include: (i) the potential to 
proliferate in vitro whilst ensuring stability of the quality; (ii) the capacity to be expanded in 
vitro so as to generate large numbers of cells to overcome the issue of tissue supply; (iii) the 
ability to be stored, ideally cryopreserved, so that batches of cells with the same quality may 
be generated and frozen for subsequent use; (iv) having the capability to be responsive to 
inductive developmental cues (i.e. exogenous factors) in order to generate the target cellular 
phenotypes for neural transplantation (i.e. for HD, striatal MSNs); and (v) following trans‐
plantation, being able to repair the circuitry damaged in the disease process and bring about 
functional recovery.
Together, these desirable traits would sidestep the issue of tissue supply and the quality 
control caveats that come with the use of primary foetal tissue, as well as standardisation 
of cells for implantation. They would also circumvent the logistical hurdles with respect to 
retrieval of tissue for dissection and preparation, and coordinating with neurosurgical teams 
for implantation procedures. However, it is paramount that any alternative donor cell source 
be able to achieve the goal of generating the specific, authentic mature phenotype following 
transplantation and then differentiation and maturation in vivo in the adult striatum.
The catalogue of alternative donor cell sources for potential use in cell replacement strategies 
for neurodegenerative diseases is predominantly comprised of expandable cells that may be 
derived from embryonic, foetal or adult tissues and may be pluripotent, multipotent or theo‐
retically, even unipotent.
Foetal neural precursors (FNPs) are multipotent cells, which are already restricted to a neural 
lineage, see [52]. Specifically, striatal FNPs are derived from foetal WGE, can be expanded in 
vitro to increase cell numbers and because of their origin of derivation may have the potential 
to differentiate more readily to a striatal phenotype. In terms of therapeutic application, the 
rationale is to expand the WGE‐derived cells in vitro to increase the total cell population and 
be able to perform one, or more, complete, bilateral transplants per foetal donor.
However, assessment of human FNPs expanded in vitro has revealed differential gene expres‐
sion between relatively early and late time points, 4–8 weeks and 20 weeks, respectively; in 
particular, revealing differences in genes is a key for providing information on positional 
identity, whilst expression of the neural markers, Nestin and Sox2, remains stable [53, 54]. 
Furthermore, there is a negative correlation between length of time in expansion culture con‐
ditions and yield of neurons upon subsequent differentiation; that is, with increased time in 
vitro, FNPs have a propensity to yield fewer neurons [55]. In addition to this, post‐transplan‐
tation, human striatal FNPs that have been expanded in culture and undergone passaging 
produce fewer surviving grafts, with reduced neuronal differentiation and a lower yield of 
striatal neurons [53, 54, 56, 57]. Thus, it appears that in vitro expansion of striatal FNPs, at 
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least long term, limits the differentiation potential of these cells, which could be due to a loss 
in positional identity over time in culture. This, in turn, would mean that when long‐term 
expanded cells are placed in an environment such as the adult brain and are not exposed to 
the developmental signals that they would see in the developing brain, they are unable to dif‐
ferentiate into phenotypes appropriate to the site from which they were derived ( e.g. MSNs 
from striatally derived FNPs).
On the other hand, short‐term expanded striatal FNPs maintained in culture for 10 days, with‐
out passaging, yielded 41% neurons, 70% of which were immunopositive for the striatal MSN 
marker DARPP‐32 (unpublished observations). Further to this, we have previously compared 
survival and axonal outgrowth of transplants of human primary foetal striatal tissue with 
short‐term expanded (10 days) striatal FNPs, where we found richer cellular outgrowth from 
the FNP‐derived grafts [58]. Recently, we have reported that striatal‐derived FNPs expanded 
for short periods in culture prior to transplantation yield the same number of DARPP‐32‐
positive neurons in grafts as those derived from primary foetal WGE [59]. Furthermore, we 
provided evidence to suggest that short‐term expanded (2 and 9 days) striatal FNPs can bring 
about a degree of functional recovery, specifically on the corridor task (testing bias towards 
the ipsilateral side and neglect of the side contralateral to the lesion and transplant), following 
transplantation into an HD rat model [59]. Collectively, this indicates that FNPs, as a potential 
donor cell source for application in clinical transplantation, should not be overlooked, but 
should be further investigated to establish their true potential.
Pluripotent stem cells (PSCs) include ES cells and iPS cells, which have the capacity to gen‐
erate any cell of the three germ layers: mesoderm, endoderm and ectoderm. Mouse ES cells 
were first identified in 1981 [60, 61], and more recently, human ES cells were also derived [62] 
from the inner cell mass of the blastocyst. iPS cells, derived from adult somatic tissues, were 
first generated in 2006, when mouse fibroblasts were re‐programmed using retrovirus‐medi‐
ated transfection and the transcription factors Oct3/4, Sox2, c‐Myc and Klf4 [63]. Later, human 
iPS cells were generated from human adult fibroblasts using the same four factors [64]. This 
seminal paper on derivation of human iPS cells showed that these cells are similar to human 
ES cells with respect to proliferation capacity, pluripotency, gene expression, morphology 
and telomerase activity [64]. The last decade has been fruitful in the publication of research 
looking at pursuing PSCs (both ES and iPS cells) as potential donor cell sources for clinical 
application. It is imperative to remember that whatever the donor source, the cells need to be 
directed to a striatal MSN phenotype.
6. Directed differentiation of PSCs towards striatal MSNs
With a focus on human‐directed differentiation studies of PSCs, we will discuss the develop‐
ment of protocols utilised in attempts to achieve striatal MSN phenotypes in vitro and in vivo. 
The key identifier used in these studies for confirmation of MSN production is DARPP‐32, 
which is expressed by more than 95% of striatal MSNs. However, it is important to note that 
DARPP‐32 is only expressed in mature MSNs and not precursor cells. Thus, when develop‐
ing protocols for the generation of such cells, particularly from PSC sources, it is vital to have 
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other markers available in order to determine that the differentiation progression is appropri‐
ate to the desired lineage and phenotype. Two such candidate markers, FoxP1 and CTIP2, 
have been identified as important markers, both of which label MSN precursor cells and co‐
label with mature DARPP‐32 immunopositive MSNs [65, 66].
Initial studies that aimed to generate striatal MSNs applied factors to influence the neural 
induction of ES cells and downregulate the pluripotent and proliferative traits of these cells. 
Neural lineage induction of human ES cells was achieved using a variety of methods, includ‐
ing culture on feeder cells prior to adherence on substrate for further differentiation, feeder 
cell‐conditioned medium and feeder‐free suspension culture [67–70]. Human ES cells cultured 
using defined neural induction medium in free‐floating suspension generated cells express‐
ing markers of immature neural precursors such as Sox1 and Pax6 [70, 71]. Terminal differen‐
tiation of these precursor cells yielded β‐III‐tubulin immunopositive neurons that expressed 
GABA (gamma amino butyric acid; the principal neurotransmitter of striatal MSNs) after 
70 days in culture [71].
More recently, a highly robust method of enhancing neural conversion of human ES cells has 
been developed utilising SMAD signalling inhibitors [72]. Specifically, addition of both nog‐
gin and SB431542 (a BMP inhibitor and Activin/Nodal inhibitor, respectively) was shown to 
increase the yield of cells expressing the neural markers Pax6, Foxg1 and Sox1, whilst expres‐
sion of the pluripotent marker Oct4 decreased [72]. This method is now widely used as the 
first stage in the generation of neural cells from PSCs and has successfully been applied to the 
initial stages of striatal differentiation protocols [73–75] (discussed below, and see Table 1).
The process of striatal neuron generation from PSCs requires exposing the cells to various 
inductive stages and ‘patterning’ them so they may obtain the desired identities, by introduc‐
ing signalling molecules indicative of regionalisation and specification, appropriate to the 
striatum. Following neural lineage induction, the cells need to be directed towards a striatal 
precursor lineage and then differentiated to generate the specific cell fate, that is, mature 
striatal MSNs.
Table 1 highlights studies that have reported protocols for differentiation of PSCs towards 
striatal neuron phenotypes, with analysis of both cultured cells in vitro and transplanted cells 
in vivo. The earliest report describing successful yield of DARPP‐32‐positive neurons from 
human ES cells used the mouse stromal feeder‐cell method to generate neural rosettes, which 
were then directed towards striatal precursors and then terminally differentiated to neurons, 
a protocol that required more than 62 days [68]. The growth factors used in this study during 
the striatal patterning phase included SHH (sonic hedgehog), DKK‐1 (Dickkopf) and BDNF 
(brain‐derived neurotrophic factor), followed by dbcAMP (dibutyryl cyclic AMP), VPA (val‐
proic acid) and BDNF for the terminal differentiation. Efficient generation of striatal MSNs 
in vitro was described, with cells expressing the striatal neuronal markers DARPP‐32, GABA, 
calbindin and calretinin. Of the 22% of total cells that were MAP2+ neurons, 53% expressed 
DARPP‐32. Although analysis of these cells following intra‐striatal implantation into a rat 
excitotoxic model of HD revealed DARPP‐32‐positive neurons within the graft region (21% of 
total neurons), transplants contained cells expressing markers of persistent proliferation and 
showed teratoma‐like overgrowth [68], thus raising issues about the efficacy of this protocol 
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Study Cell lines Protocol DARPP‐32+ neurons 
in vitro
Day of analysis/
observations
DARPP‐32+ neurons in 
vivo
Day of transplantation/
observations
Aubry et al. 
[68]
Human ES 
cells:
SA‐01 & H9
Neural induction in serum‐
free and N2‐supplemented 
medium for 21–23 days; striatal 
patterning with addition of 
BDNF, SHH & DKK‐1 (days 
46–59); neuronal differentiation 
with dbcAMP, VPA & BDNF 
(continued > day 62)
Between days 62–72:
22% total cells were 
MAP2+ neurons, 
53% neurons were 
DARPP‐32+
Day 59:
DARPP‐32+ cells at 
4–6 weeks and 13–21 weeks 
post‐transplantation; 
DARPP32+cells made up 
21% neurons at 13 weeks, 
with no difference at later 
time points
Ma et al. [76] Human ES 
cells:
H9
Neural induction in serum‐free 
and N2‐supplemented medium 
for 10–12 days; striatal pat‐
terning with SHH or purmor‐
phamine (to day 26), then VPA 
(to day 32); neuronal differentia‐
tion with BDNF, GDNF, IGF, 
AA &cAMP (to day 47)
Day 47: 93% total cells 
were β‐III‐tubulin+ 
neurons, 90% neurons 
were GABA+, 
∼90% GABA+ were 
DARPP‐32+
Day 40:
DARPP‐32+ 
cells at 4 months 
post‐transplantation;
DARPP‐32+/GABA+ 
neurons were 58% total 
graft‐derived cells
Delli‐Carri 
et al. [73]
Human ES 
cells:
H9 & HS401
Human iPS 
cells:
DF3F & WT 
iPS 3F‐1
Neural induction in serum‐
free medium with increasing 
concentration of N2‐
supplementation and addition 
of dorsomorphin, noggin, 
SB431542; addition of SHH & 
DKK‐1; neuronal differentiation 
with N2, B27 & BDNF
Day 45: 80% of cells 
were β‐III‐tubulin+ 
neurons, majority were 
GABA+ some of which 
were DARPP‐32+.
Day 80: 51% total cells 
were Map2ab+ neurons, 
20% neurons were 
DARPP‐32+
Day 38:
DARPP‐32+ cells at 9 weeks 
post‐transplantation were 
0.05% of total graft‐derived 
cells
Nicoleau et 
al. [74]
Human ES 
cells:
H9 & RC9
Human iPS 
cells:
I90c17
Neural induction with LDN 
(or noggin) & SB431542 for 
10 days; further 10 days in 
N2/B27 medium; neuronal 
differentiation with BDNF, 
dbcAMP & VPA; (also 
tested addition of SHH or 
cyclopamine, and Wnt3a, DKK‐1 
or XAV‐939)
Day 20 differentiated 
for a further 25 days: 
DARPP‐32+ neurons 
present (optimal with 
1μm XAV)
Longer term for 
>60 days: DARPP‐32+ 
neurons, with 23 fold 
more expression at day 
60 than day 10
Day 25:
DARPP‐32+ neurons 
extensive throughout 
grafts 5 months 
post‐transplantation
Arber et al. 
[75]
Human ES 
cells:
H1 & H7
Human iPS 
cells:
2F8 & 4FH
Neural induction in N2/B27 
medium with SB431542 (up 
to day 5), LDN (or noggin) & 
dorsomorphin (up to day 9); 
addition of Activin A from day 9 
(to day 20); terminal differentia‐
tion with BDNF & GDNF
Day 36–40: DARPP‐32+ 
neurons, QPCR,5 fold 
increase with Activin 
treatment than without;
ICC,20–50% DARPP‐32+ 
(depending on cell line)
Day 20:
DARPP‐32+ cells 8 weeks 
post‐transplantation 
(very few); 16 weeks 
post‐transplantation, 
49% HuNu+ cells were 
DARPP‐32+
Abbreviations: BDNF, brain‐derived neurotrophic factor; SHH, Sonic Hedgehog; DKK‐1, Dickkopf; dbcAMP, dibutyryl 
cyclic AMP; VPA, valproic acid; GDNF, glial‐derived neurotrophic factor; IGF, insulin growth factor; AA, ascorbic acid; 
FGF, fibroblast growth factor; XAV‐939, chemical antagonist of Wnt/β‐catenin pathway (substitute for DKK‐1) (Wnt 
inhibitor molecule); QPCR, semi‐quantitative real‐time polymerase chain reaction analysis; ICC, immunocytochemistry; 
HuNu, human nuclei; DARPP‐32, dopamine‐ and cyclic‐AMP‐regulated phosphoprotein of molecular weight 32 kDa; 
GABA, gamma amino butyric acid.
Table 1. Studies reporting in vitro and in vivo analysis of striatal differentiation protocols with human pluripotent stem cells.
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and highlighting the importance of in vivo verification post in vitro differentiation. A short‐
ened neural induction period for generation of neuroepithelial cells followed by addition of 
SHH or purmorphamine (a SHH agonist), then VPA and finally BDNF, GDNF (glial‐derived 
neurotrophic factor), IGF (insulin growth factor), ascorbic acid and cAMP yielded striatal 
neurons after 47 days [76]. Specifically, of the β‐III‐tubulin‐positive neurons (93% of total 
cells), 90% expressed GABA, and 90% of these GABAergic neurons expressed DARPP‐32 [76]. 
DARPP‐32 immunopositive cells were observed in vivo, at 4 months after transplantation into 
an excitotoxic lesioned mouse model, with DARPP‐32‐positive/GABA‐positive neurons mak‐
ing up 58% of total grafted cells. Behavioural analysis revealed improvements in transplanted 
mice on various tests including the rotarod test of motor control, open‐field measures such as 
crossings and total distance moved, and increased stride length on the Treadscan test for gait 
analysis. Again, it is important to note that whilst the authors claim no graft overgrowth, the 
number of total cells in the grafts at the time of analysis was greater than 3 million, whilst only 
100,000 cells were transplanted. Taken together, these data showed the successful generation 
of MSNs that had the capacity to alleviate some of the locomotor deficits seen in this model of 
HD. Reproduction of this effect has not been reported, despite numerous attempts by others, 
and so caution must be taken in the interpretation of these findings.
The first report of striatal differentiation from PSCs that utilised the dual SMAD protocol for 
neural induction, previously mentioned [72], used SB431542, noggin and dorsomorphin, for 
the initial neural induction phase, with subsequent addition of SHH and DKK‐1, and later 
BDNF [73]. After 45 days in vitro, GABA‐positive/DARPP‐32‐positive cells were observed, 
and by day 80, 20% of Map2ab+ neurons (51% of total cells) expressed DARPP‐32. Following 
transplantation into a lesioned rat striatum, a modest functional improvement was reported 
(on an apomorphine‐induced rotation test), as early as 3‐week post‐transplantation, which 
was maintained at 6 weeks, but fell short of significance at 9‐week post‐transplantation. 
Additionally, FoxP1‐positive cells and a small number of graft‐derived DARPP‐32‐positive 
neurons were seen [73]. A total of 4 million cells per graft were reported at 9‐week post‐trans‐
plantation (following transplantation of 500,000 cells), with approximately 2000 DARPP‐32‐
positive cells per graft (0.05%). Again, caution must be conveyed in interpreting these data as 
the number of animals was low for confirmation of a significant effect, and with respect to the 
in vivo DARPP‐32 staining presented, the numbers seen were very low.
Another study that employed the dual SMAD inhibition protocol using SB431542 and LDN 
or noggin also looked at the effects of addition of SHH or cyclopamine (a SHH antagonist), 
and Wnt3a, DKK‐1 or XAV‐939 (the latter two being Wnt pathway inhibitors) [74]. Striatal 
neurons expressing DARPP‐32, calbindin and calretinin were yielded after 45 days in culture, 
with a combination of XAV‐939 (1 μM) or DKK‐1 (100 ng/ml), and SHH (50 ng/ml) resulting in 
optimal numbers of DARPP‐32  immunopositive cells (∼25% of MAP2‐positive neurons). With 
longer time periods in culture (>60 days), increased expression  of DARPP‐32 was observed, as 
well as expression of other striatal neuron markers including CTIP2, dopamine receptors D1 
and D2, calbindin and substance P [74]. Analysis of these cells at 5‐month post‐transplanta‐
tion showed expression of DARPP‐32‐positive neurons throughout grafts that co‐expressed 
FoxP1 and CTIP2. In addition, grafts were seen to take over most of the host striatum, although 
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assessment of proliferative markers, markers of cells from different lineages or total cell num‐
bers were not reported [74].
A novel striatal conversion protocol, still utilising dual SMAD inhibition for the initial neural 
induction phase, but introducing Activin A in the patterning stage and reporting the redun‐
dance of SHH, resulted in DARPP‐32‐positive neurons after 36–40 days in vitro [75]. The 
numbers of DARPP‐32‐positive neurons yielded in vitro ranged from 20 to 50%, depending 
on the PSC line being assessed, and expression of striatal markers calbindin and CTIP2 was 
also reported. Although no functional effect was seen in vivo after transplantation of these 
cells, the striatal neuronal differentiation reported was considerably better than in previous 
studies [75]. Most graft‐derived cells expressed GABA, and DARPP‐32‐positive neurons com‐
prised 49% of total graft‐derived cells. Other striatal phenotypes observed were calbindin, 
FoxP2, dopamine receptor D2 and substance P. The proliferative marker, Ki‐67, was detected 
at 4‐week post‐transplantation, but was absent from grafts at 16‐week post‐transplantation. 
Furthermore, the largest graft comprised approximately 500,000 cells (determined by assess‐
ment of human nuclei immunostaining), at 16‐week post‐transplantation, following engraft‐
ment of 400,000 cells per graft [75].
The characteristics of human‐derived MSNs at an electrophysiological level are not well 
described. We have previously used calcium imaging analysis to look at neuronal differentia‐
tion and functional cellular activity of primary human foetal‐derived MSNs [7]. Exposing the 
in vitro differentiated neurons to various stimuli and neurotransmitter applications resulted 
in rises in intracellular calcium concentration. Stimuli used included GABA, NMDA, AMPA, 
kainate, L‐glutamate, all of which are indicators of striatal function. A noteworthy finding is 
that observed following application of GABA, which showed an increase in intracellular cal‐
cium and therefore demonstrated a voltage‐activated calcium influx in response to a degree 
of depolarisation. This is indicative of a foetal phenotype, rather than adult. Thus, this study 
showed that even after 24 days in vitro, the differentiated neurons still exhibited a foetal phe‐
notype [7]. Apart from this preliminary analysis, little is known about the functional capacity 
of human‐derived MSNs in vitro.
In comparison, some of the studies described above that generated MSNs from human PSCs 
have progressed further in understanding such characteristics. ES cell‐derived neurons were 
reported to be mature and functional after 4 weeks in culture [71]. In this study, where there 
was no specific patterning towards striatal cell fates, neurons exhibited whole‐cell currents 
including fast, voltage‐activated and rapidly inactivating inward currents followed by slowly 
activated but sustained outward currents, and when stimulated generated action potentials. 
When differentiation of PSCs was directed towards a striatal MSN phenotype, generation of 
functional striatal neurons from PSCs has been confirmed [73, 75, 76]. Specifically, genera‐
tion of GABAergic neurons was confirmed by stimulation with a high‐potassium solution 
and subsequent measurement of the levels of GABA released, which showed that these cells 
produced a significantly greater amount of GABA than GABA interneurons [76]. In addi‐
tion, these cells had the potential to generate action potentials following whole‐cell patch 
clamping. Striatal neurons derived using protocols combining the dual SMAD inhibition 
method for neural induction followed by striatal patterning were shown to have the capacity 
Transplantation in HD: Are We Transplanting the Right Cells?
http://dx.doi.org/10.5772/66490
131
to function in a network, forming synapses and showing responsiveness to GABAergic and 
dopaminergic stimulation [73]. Furthermore, PSC‐derived MSNs showed the ability to form 
GABAergic synapses and exhibited responses to a stimulus and delayed action potential fir‐
ing typical of striatal MSNs [75]. These are crucial steps in validating the potential of these 
cells for use in transplantation.
One issue with the use of PSCs as donor cell sources is the exclusivity, initially with respect 
to neuralisation, and later ‘striatalisation’, of the ‘induction‐patterning‐differentiation’ proto‐
cols applied. Thus, this begs the questions: ‘How heterogeneous is the resultant population 
with respect to cell types of other, perhaps, unwanted lineages?’ and ‘How much of a prob‐
lem is this?’ Certainly, the continued presence of undifferentiated PSCs and/or unrestrained 
proliferative cells in the culture system immediately prior to engraftment makes these cells 
less attractive as a prospect for transplantation due to the potential risk of uncontrolled over‐
growth and even generation of teratomas.
It is clear that the directed differentiation of PSCs in vitro can yield functional striatal MSNs, 
albeit with varied times in culture and application of different signalling combinations at the 
different stages of the differentiation process. Transplantation of PSCs into animal models 
of HD has met with mixed fortunes with the majority of studies exhibiting overgrowth and 
teratoma formation in the host brain post‐transplantation, thus emphasizing the importance 
of in vivo validation of in vitro cell generation. Identifying a more refined growth factor/signal‐
ling molecule cocktail may, perhaps, be a necessary prelude to using these cells for clinical 
transplantation application. This work is actively ongoing in many laboratories and forms 
a key part of the European funded ‘Repair HD’ consortium. What is lacking at this point is 
a detailed understanding of the potential of human foetal‐derived MSNs to function, as the 
analysis to date is limited.
7. Concluding remarks
We have discussed here the current status of neural transplantation in HD and considered 
the promise shown by clinical trial data, which have provided proof of principle that the 
approach works in many cases. However, it is evident that there is still a long way to go, and 
the challenge for generation of successful, efficacious, reproducible transplants is still large. 
We have highlighted the importance of assessing functional readouts of grafts and not relying 
solely on histological assessments. Equally, with potential alternative donor cells, it is critical 
to undertake in vivo assessments of cells differentiated from these sources, understanding that 
the in vitro data are just a prelude to the necessary in vivo analysis.
Furthermore, we highlighted the limited preclinical data with respect to human‐to‐rodent 
investigations, which would advance our understanding of transplanted striatal MSNs 
derived from both human primary foetal tissue and PSCs. In addition, we see the requirement 
for future transplant experiments to seek to incorporate neurorehabilitation post‐transplanta‐
tion, in the form of training the graft and also environmental enrichment, as this may well 
impact on the findings pertaining to the donor cell source.
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It appears very probable that an expandable donor cell source will be utilised in future clinical 
transplant trials, and we have discussed here reports of directed differentiation of such sources 
to MSNs, albeit with varying degrees of success. However, it is important to continue to gain 
understanding of human primary foetal striatal cells, including aspects of their development, 
physiological assessments both in vitro and in vivo, and their ability to generate effective trans‐
plants, restoring functional deficits seen in different HD models. This will be the foundation 
against which all possible alternatives should be compared as part of any preclinical validation.
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HD Huntington's disease
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WGE Whole ganglionic eminence
MTOP Medical termination of pregnancy
STOP Surgical termination of pregnancy
MRI Magnetic resonance imaging
UHDRS Unified HD rating scale
PET Positron emission tomography
CAPIT‐HD  Core Assessment Program for Intracerebral Transplantation in Huntington's 
Disease
AChE Acetylcholinesterase
DARPP‐32  Dopamine‐ and cyclic‐AMP‐regulated phosphoprotein of molecular weight 
32 kDa
ES Embryonic stem
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PSC Pluripotent stem cell
LTP Long‐term potentiation
GABA Gamma amino butyric acid
SHH Sonic hedgehog
DKK‐1 Dickkopf
BDNF Brain‐derived neurotrophic factor
GDNF Glial‐derived neurotrophic factor
VPA Valproic acid
dbcAMP Dibutyryl cyclic AMP
IGF Insulin growth factor
NMDA N‐methyl‐D‐aspartic acid
AMPA α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate
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